Muestra la distribución de la producción WoS, Scopus y SciELO del autor.
Publicaciones WoS (Ediciones: ISSHP, ISTP, AHCI, SSCI, SCI), Scopus, SciELO Chile.
Departamento Gestión de Conocimiento, Monitoreo y Prospección
Consultas o comentarios: productividad@anid.cl
Consultas o comentarios: productividad@anid.cl
| Firmas del autor | |
| Nombre | MANZOR, MANUEL |
| Género | Hombre |
| Área Principal WOS | Oncology; Gastroenterology & Hepatology; |
| Afiliación Principal | Hospital Dr Sotero Del Rio |
ORCID
|
0000-0003-1340-7726 |
Publicaciones en Chile
Citas Totales
Afiliaciones Chilenas
Periodo registrado: 2008 - 2025
| WOS | #Pub |
|---|---|
| Oncology | 5 |
| Gastroenterology & Hepatology | 1 |
| Scopus | #Pub |
|---|---|
| Oncology | 1 |
| Cancer Research | 1 |
| SciELO | #Pub |
|---|
| Institución | # Pub |
|---|---|
| Hospital Dr Sotero Del Rio | 5 |
| Pontificia Universidad Católica De Chile | 1 |
| Hospital Dr | 1 |
| Año | Firma | Institución (Incites asoc.) | H Index | Average Percentile | Impact Citation | Impact Relative World | Impact Journal Normalized Citation | Impact Category Normalized Citation | Percentage Cited | Percentage Top 1 | Percentage Top 10 | Percentage Journal Q1 | Percentage Journal Q2 | Percentage Journal Q3 | Percentage Journal Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2019 | Manzor, Manuel | Pontificia Universidad Catolica de Chile | 1.0 | 81.2 | 1.0 | 0.1 | 0.4 | 0.2 | 100.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 100.0 |
| 2024 | Manzor, Manuel | Universidad de Chile | 3.0 | 31.1 | 0.0 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 28.6 | 0.0 | 0.0 | 0.0 |
| Palabra Clave | #Pub |
|---|---|
| women | 3 |
| estrogen | 3 |
| prognosis | 3 |
| breast neoplasm | 3 |
| therapy | 2 |
| survival | 2 |
| breast cancer | 2 |
| pertuzumab | 1 |
| phase-2 | 1 |
| placebo | 1 |
| patterns | 1 |
| premenopausal women | 1 |
| letrozole | 1 |
| public hospital | 1 |
| receptors | 1 |
| reconstruction | 1 |
| ovarian | 1 |
| recurrence | 1 |
| risk assessment breast | 1 |
| risk factors | 1 |
| safety | 1 |
| stomach neoplasms | 1 |
| subtypes | 1 |
| system | 1 |
| tamoxifen | 1 |
| trastuzumab | 1 |
| triple negative | 1 |
| drug therapy | 1 |
| access disparities | 1 |
| adjuvant endocrine therapy | 1 |
| age | 1 |
| alpelisib plus fulvestrant | 1 |
| association | 1 |
| body-mass index | 1 |
| brca | 1 |
| breast cancer in young women | 1 |
| carboplatin | 1 |
| circular-stapled esophagojejunostomy | 1 |
| consensus | 1 |
| oophorectomy | 1 |
| esophagojejunostomy | 1 |
| experience | 1 |
| gastrectomy | 1 |
| germinal gene testing | 1 |
| impact | 1 |
| inhibitor | 1 |
| laparoscopy | 1 |
| latin american | 1 |
| latin-american | 1 |
| abemaciclib | 1 |
| neoadjuvant therapy | 1 |
Descargar
Descarga los datos de esta página (formato JSON).
Descargar
Descarga los datos de esta página como un archivo Excel.
